Following the announcement yesterday that Sanofi’s (Euronext: SAN) global head of R&D John Reed is leaving the French drugmaker, his destination has been revealed as the US healthcare giant Johnson & Johnson (NYSE: JNJ).
Dr Reed joins the group’s executive committee as executive vice president of Pharmaceuticals, R&D, assuming responsibility for the company’s portfolio. He will start his new role on April 3, taking over from William Hait, who had been interim head of J&J’s Pharmaceutical R&D organization since August 2022.
"An extraordinary track record for discovering and developing life-saving innovations"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze